PDF(Pubmed)
Abstract：
BACKGROUND: This multicenter retrospective study aimed to investigate the prognostic value of the CA-125 elimination rate constant K (KELIM) in EOC patients who received platinum-based chemotherapy followed by PARP inhibitors, in either upfront or interval treatment settings.
METHODS: Between July 2019 and November 2022, we identified stage III-IV EOC patients who underwent primary or interval cytoreductive surgery and received olaparib or niraparib. Individual KELIM values were assessed based on validated kinetics and classified into favorable and unfavorable cohorts.
RESULTS: In a study of 252 patients undergoing frontline maintenance therapy with olaparib or niraparib, favorable KELIM (≥1) scores were associated with a higher PFS benefit in the primary cytoreductive surgery (PCS) cohort (hazard ratio (HR) for disease progression or death 3.51, 95% confidence interval (CI); 1.37-8.97, p = 0.009). Additionally, within the interval cytoreductive surgery (ICS) cohort, a favorable KELIM score (≥1) significantly increased the likelihood of achieving complete resection following cytoreductive surgery, with 59.4% in the favorable KELIM group compared to 37.8% in those with unfavorable KELIM.
CONCLUSIONS: A favorable KELIM score was associated with improved PFS in patients with advanced EOC undergoing PCS. Furthermore, in the ICS cohort, a favorable KELIM score increased the probability of complete cytoreduction.
METHODS: Between July 2019 and November 2022, we identified stage III-IV EOC patients who underwent primary or interval cytoreductive surgery and received olaparib or niraparib. Individual KELIM values were assessed based on validated kinetics and classified into favorable and unfavorable cohorts.
RESULTS: In a study of 252 patients undergoing frontline maintenance therapy with olaparib or niraparib, favorable KELIM (≥1) scores were associated with a higher PFS benefit in the primary cytoreductive surgery (PCS) cohort (hazard ratio (HR) for disease progression or death 3.51, 95% confidence interval (CI); 1.37-8.97, p = 0.009). Additionally, within the interval cytoreductive surgery (ICS) cohort, a favorable KELIM score (≥1) significantly increased the likelihood of achieving complete resection following cytoreductive surgery, with 59.4% in the favorable KELIM group compared to 37.8% in those with unfavorable KELIM.
CONCLUSIONS: A favorable KELIM score was associated with improved PFS in patients with advanced EOC undergoing PCS. Furthermore, in the ICS cohort, a favorable KELIM score increased the probability of complete cytoreduction.
摘要：
背景：这项多中心回顾性研究旨在研究CA-125消除率常数K（KELIM）在接受铂类化疗后加PARP抑制剂的EOC患者中的预后价值，在前期或间歇治疗设置中。
方法：在2019年7月至2022年11月之间，我们确定了III-IV期EOC患者接受了初次或间期细胞减灭术并接受奥拉帕尼或尼拉帕尼。根据验证的动力学评估个体KELIM值，并将其分为有利和不利的队列。
结果：在接受奥拉帕尼或尼拉帕尼一线维持治疗的252例患者的研究中，在原发性细胞减灭术(PCS)队列中,有利的KELIM(≥1)评分与较高的PFS获益相关(疾病进展或死亡的风险比(HR)3.51,95%置信区间(CI);1.37~8.97,p=0.009).此外,在间隔细胞减灭术（ICS）队列中，良好的KELIM评分(≥1)显著增加了细胞减灭术后实现完全切除的可能性,有利的KELIM组为59.4%，而不利的KELIM组为37.8%。
结论：在接受PCS的晚期EOC患者中，良好的KELIM评分与PFS改善相关。此外，在ICS队列中，良好的KELIM评分增加了完全细胞减少的可能性.
方法：在2019年7月至2022年11月之间，我们确定了III-IV期EOC患者接受了初次或间期细胞减灭术并接受奥拉帕尼或尼拉帕尼。根据验证的动力学评估个体KELIM值，并将其分为有利和不利的队列。
结果：在接受奥拉帕尼或尼拉帕尼一线维持治疗的252例患者的研究中，在原发性细胞减灭术(PCS)队列中,有利的KELIM(≥1)评分与较高的PFS获益相关(疾病进展或死亡的风险比(HR)3.51,95%置信区间(CI);1.37~8.97,p=0.009).此外,在间隔细胞减灭术（ICS）队列中，良好的KELIM评分(≥1)显著增加了细胞减灭术后实现完全切除的可能性,有利的KELIM组为59.4%，而不利的KELIM组为37.8%。
结论：在接受PCS的晚期EOC患者中，良好的KELIM评分与PFS改善相关。此外，在ICS队列中，良好的KELIM评分增加了完全细胞减少的可能性.
